BridgeMD
New treatment option for Kidney Transplant Rejection
Official title Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab
ClinicalTrials.gov ID: NCT07006532
What this study is testing
What is Tocilizumab?
Tocilizumab is an investigational medicine, being studied as a potential treatment for kidney transplant rejection.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Chronic active antibody mediated rejection (CAMR) is a therapeutic challenge in transplant recipients that does not respond well to conventional treatments for acute antibody mediated rejection (AMR). Annually, 5000 kidney transplants are lost in the United States due to CAMR.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Signed written informed consent
- eGFR\> 25 cc/min
- Chronicity index \<8
- IFTA\<40%
- EBV IgG positive
You likely can't join if
- Active or recurrent infections
- History of malignancy, unless in remission for more than 2 years with no relapse
- abnormal liver function tests
- Platelet \< 100,000
The study team makes the final eligibility decision.
Where it's taking place
- Tehran, Iran
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tehran, Iran. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.